TY - JOUR
T1 - Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases
AU - Fenster, Marc
AU - Ungaro, Ryan C.
AU - Hirten, Robert
AU - Gallinger, Zane
AU - Cohen, Louis
AU - Atreja, Ashish
AU - Mehandru, Saurabh
AU - Colombel, Jean Frederic
AU - Cohen, Benjamin L.
N1 - Funding Information:
Funding Ashish Atreja is supported by an NIH 1K23DK097451-01A1 award. Louis Cohen is supported by a Crohn's and Colitis Foundation Career Development Award and NIDDK K08 DK109287-01. Zane Gallinger is supported by a Canadian Association of Gastroenterology grant. Robert Hirten is supported by a Career Development Award from the Crohn's and Colitis Foundation (Award number 607934). Saurabh Mehandru is supported by the Kenneth Rainin Foundation Synergy Award. Ryan Ungaro is supported by NIH NIDDK K23 Career Development Award (K23KD111995-01A1).
Publisher Copyright:
© 2020 AGA Institute
PY - 2020/1
Y1 - 2020/1
N2 - Inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous infusion.1-4 Historically, intravenous infusions of infliximab and vedolizumab in patients with IBD were delivered under direct supervision of clinicians in infusion centers at hospitals or clinics. Recently, intravenous infusions have transitioned into patient homes. Professional societies have differed on their recommendations for biologic home infusions (HI),5,6 yet limited data exist on the safety and efficacy of HI programs.7,8 Therefore, the primary aim of this study was to compare adverse outcomes (AOs), as defined as a composite of stopping therapy, IBD-related emergency-room (ER) visit, or IBD-related hospitalization, in patients with IBD receiving biologics as HI or at a hospital-based infusion center.
AB - Inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous infusion.1-4 Historically, intravenous infusions of infliximab and vedolizumab in patients with IBD were delivered under direct supervision of clinicians in infusion centers at hospitals or clinics. Recently, intravenous infusions have transitioned into patient homes. Professional societies have differed on their recommendations for biologic home infusions (HI),5,6 yet limited data exist on the safety and efficacy of HI programs.7,8 Therefore, the primary aim of this study was to compare adverse outcomes (AOs), as defined as a composite of stopping therapy, IBD-related emergency-room (ER) visit, or IBD-related hospitalization, in patients with IBD receiving biologics as HI or at a hospital-based infusion center.
UR - http://www.scopus.com/inward/record.url?scp=85076838357&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2019.03.030
DO - 10.1016/j.cgh.2019.03.030
M3 - Short survey
C2 - 30910602
AN - SCOPUS:85076838357
SN - 1542-3565
VL - 18
SP - 257
EP - 258
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 1
ER -